Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

  1. Ciruelos, E.
  2. Alba, E.
  3. López, R.
  4. Lluch, A.
  5. Martín, M.
  6. Arroyo, I.
  7. Navarro, B.
  8. Carcedo, D.
  9. Colomer, R.
  10. Albanell, J.
Revista:
Oncotarget

ISSN: 1949-2553

Any de publicació: 2019

Volum: 10

Número: 42

Pàgines: 4321-4332

Tipus: Article